Log in

HemaCare Stock Forecast, Price & News

+0.15 (+0.60 %)
(As of 01/3/2020)
Today's Range
Now: $25.31
50-Day Range
MA: $25.31
52-Week Range
Now: $25.31
Volume5,400 shs
Average Volume39,950 shs
Market Capitalization$346.52 million
P/E RatioN/A
Dividend YieldN/A
HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy. It offers human blood cellular components derived from peripheral blood, bone marrow, and cord blood; and a range of consulting services in standard operating procedure development, personnel training, and quality and regulatory compliance. The company's network of FDA-registered, GMP/GTP-compliant collection centers ensures donor materials available to customers, as well as for use within its isolation laboratory. The company has strategic partnership with Charles River Laboratories International Inc. for human immune system research. HemaCare Corporation was founded in 1978 and is headquartered in Northridge, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Current SymbolOTCMKTS:HEMA



Sales & Book Value

Annual SalesN/A



Market Cap$346.52 million
Next Earnings DateN/A
OptionableNot Optionable
+0.15 (+0.60 %)
(As of 01/3/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive HEMA News and Ratings via Email

Sign-up to receive the latest news and ratings for HEMA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

HemaCare (OTCMKTS:HEMA) Frequently Asked Questions

How has HemaCare's stock price been impacted by COVID-19?

HemaCare's stock was trading at $25.31 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HEMA shares have increased by 0.0% and is now trading at $25.31.
View which stocks have been most impacted by COVID-19

Who are some of HemaCare's key competitors?

What other stocks do shareholders of HemaCare own?

Who are HemaCare's key executives?

HemaCare's management team includes the following people:
  • Mr. Peter C. van der Wal, Pres, CEO & Director (Age 62)
  • Ms. Rochelle J. Martel M.B.A., CPA, Chief Financial Officer
  • Ms. Maria Pia Muniz, Sr. VP of Operations
  • Mr. Lou Juliano, Sr. VP of Global Sales & Bus. Devel.
  • Dr. Dominic Clarke, Global Head of Cell Therapy

What is HemaCare's stock symbol?

HemaCare trades on the OTCMKTS under the ticker symbol "HEMA."

How do I buy shares of HemaCare?

Shares of HEMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is HemaCare's stock price today?

One share of HEMA stock can currently be purchased for approximately $25.31.

How big of a company is HemaCare?

HemaCare has a market capitalization of $346.52 million.

What is HemaCare's official website?

The official website for HemaCare is www.hemagen.com.

How can I contact HemaCare?

HemaCare's mailing address is 15350 SHERMAN WAY SUITE 350, VAN NUYS CA, 91406. The company can be reached via phone at 818-226-1968 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.